Skinvisible, Inc. (SKVI): Total Liabilities
$10.39M
As of 2025-12-31
$10.91M
As of 2026-06-30
+14.7%
3-year compound annual growth
+17.4%
5-year compound annual growth
+5.5%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.39M | +10.8% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $9.38M | +2.1% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $9.19M | +33.4% | 2025-04-14, Balance as of period end |
| 2022-12-31 | $6.89M | +22.1% | 2024-04-16, Balance as of period end |
| 2021-12-31 | $5.64M | +21.2% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $4.66M | +46.0% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $3.19M | -35.4% | 2021-04-15, Balance as of period end |
| 2018-12-31 | $4.94M | -33.2% | 2020-05-14, Balance as of period end |
| 2017-12-31 | $7.39M | +14.6% | 2019-04-15, Balance as of period end |
| 2016-12-31 | $6.45M | +6.4% | 2018-03-23, Balance as of period end |
| 2015-12-31 | $6.06M | +21.3% | 2017-04-17, Balance as of period end |
| 2014-12-31 | $5.00M | +38.4% | 2016-04-14, Balance as of period end |
| 2013-12-31 | $3.61M | +52.2% | 2015-03-31, Balance as of period end |
| 2012-12-31 | $2.37M | +127.9% | 2014-04-11, Balance as of period end |
| 2011-12-31 | $1.04M | -20.2% | 2013-04-16, Balance as of period end |
| 2010-12-31 | $1.31M | n/a | 2012-11-19, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Skinvisible, Inc. (SKVI) | 2025-12-31 | $10.39M | +10.8% |
| Jupiter Neurosciences, Inc. (JUNS) | 2025-12-31 | $7.40M | +264.3% |
| Bioadaptives, Inc. (BDPT) | 2025-12-31 | $2.36M | +36.5% |
| PRF Technologies Ltd. (PRFX) | 2025-12-31 | $2.71M | +0.3% |
| Talphera, Inc. (TLPH) | 2025-12-31 | $12.68M | +23.9% |
| Impact Biomedical Inc. (IBO) | 2025-12-31 | $1.85M | -85.8% |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $91.85M | -15.0% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $20.33M | +127.9% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $55.04M | +248.4% |
Compare SKVI, JUNS, BDPT, PRFX side by side · Screen every company in Pharmaceutical Preparations ↗